Obesity-related immune dysregulation creates a favorable environment for increased PD-1/PD-L1 inhibitor efficacy by inducing tumor-intrinsic, microenvironmental, and systemic changes [15]. This evidence concerns the gene PDCD1 and obesity due to melanocortin 4 receptor deficiency.